Please login to the form below

Not currently logged in
Email:
Password:

Pfizer’s investigational leukaemia drug wins breakthrough status

Puts inotuzumab ozogamacin in line for development incentives
Pfizer

Pfizer's investigational inotuzumab ozogamacin has received breakthrough therapy designation from the FDA for acute lymphoblastic leukaemia (ALL). 

The decision comes on the back of data from the phase III INO-VATE ALL trial involving 326 patients with relapsed or refractory ALL which showed that inotuzumab outperformed current standards of care.

The co-primary endpoint of complete remission with incomplete haematologic recovery was achieved by 80.7% for those given inotuzumab versus 33.3% for those given standard care.

Inotuzumab is an investigational antibody-drug conjugate (ADC), which includes a monoclonal antibody targeting CD22. When inotozumab binds to the CD22 antigen on malignant B-cells, it is internalised into the cell where the cytotoxic agent calicheamicin is released and destroys the cell.

Mace Rothenberg, senior VP of clinical development and medical affairs at Pfizer, said: “Inotozumab ozogamicin is the third Pfizer oncology medicine to be granted breakthrough therapy designation by the FDA, underscoring our commitment to innovative research and development that addresses significant unmet needs.

“Advancing therapies for patients with adult acute lymphoblastic leukaemia is crucial as only 10% of adults with ALL who relapse after first-line therapy survive five years or more with current treatment options.”

Inotuzumab recently failed to improve overall survival in patients with non-Hodgkin's lymphoma, so the designation will come as good news for Pfizer now that the drug looks to be back on track for regulatory approval.

ALL affects about 6,000 Americans every year with only 20-40% of newly diagnosed adults being cured with current treatment regimens.

The FDA's breakthrough therapy designation was launched in 2012 and is intended to expedite the development and review of medicines for life-threatening diseases where clinical evidence suggests it offers an improvement over current therapies.

Pfizer's other oncology medications which received breakthrough therapy designation are Ibrance (palbociclib) and Xalkori (crizotinib). According to analysts, Ibrance, which was approved for breast cancer earlier this year, could achieve sales of at least $3bn.  

Article by
Nikhil Patel

20th October 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics